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Previously, priming with replication-competent adenovirus-SIV multigenic vaccines and boosting with envelope subunits strongly protected
39% of rhesus macaques against rectal SIVmac251 challenge. To evaluate protection durability, eleven of the protected and two SIV-infected
unimmunized macaques that controlled viremia were re-challenged rectally with SIVmac251. Strong protection was observed in 8/11 vaccinees,
including two exhibiting <50 SIV RNA copies. Decreased viremia compared to naïve controls was observed in the other three. The SIV-infected
unimmunized macaques modestly controlled viremia but exhibited CD4 counts ≤200, unlike the protected macaques. Durable protection was
associated with significantly increased SIV-specific ELISPOT responses and lymphoproliferative responses to p27 at re-challenge. After CD8
depletion, 2 of 8 re-challenged, protected vaccinees maintained <50 SIV RNA copies; SIV RNA emerged in 6. Re-appearance of CD8 cells and
restoration of SIV-specific cellular immunity coincided with viremia suppression. Overall, cellular immunity induced by vaccination and/or low-
level, inapparent viremia post-first SIVmac251 challenge, was associated with durable protection against re-challenge.
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An efficient AIDS vaccine will require long-lasting
immunity in order to protect against repeated HIV exposures.
Live, attenuated SIV vaccines provide low-level expression of
viral proteins, thus inducing vigorous antiviral immunity that
results in effective protection against repeated challenges with⁎ Corresponding author. Fax: +1 301 402 0055.
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doi:10.1016/j.virol.2006.05.012pathogenic SIV (Connor et al., 1998; Daniel et al., 1992;
Stebbings et al., 2002). However, some studies have shown
that infection with attenuated SIV leads to a high level of
viremia and disease progression in infant and adult macaques
(Baba et al., 1995, 1999; Gundluch et al., 2000; Hofmann-
Lehmann et al., 2003). Unless such attenuated viruses can be
appropriately engineered and proven to be safe, the next best
option may be provided by live, replicating vectors (Mal-
kevitch and Robert-Guroff, 2004). We have been developing
replication-competent adenovirus (Ad) vectors as vehicles for
AIDS vaccines. Our studies in both chimpanzee and rhesus
macaque models have demonstrated that priming with
replicating Ad recombinants encoding HIV or SIV genes
Table 1
Immunization, challenge history, and second challenge of macaques in the study
Macaque Ad5hr-SIV
recombinant prime a
(weeks 0, 12)
encoding:
Envelope
subunit boost b
(weeks 24 and 36)
1st IR
challenge
(week 42)
2nd IR
challenge
(week 105 c)
Macaques previously protected against 1st challenge
5 SIVenv/rev SIV peptomer SIVmac251 SIVmac251
7 " " " "
9 " " " "
28 SIVenv/rev +
SIVgag
Native
SIVgp120 in
MPL-SE
" "
15 SIVenv/rev +
SIVgag +
SIVnefΔ1-19
" " "
33 " " " "
41 " " " "
4 SIVenv/rev +
SIVnefΔ1-19
" " "
29 " " " "
32 " " " "
40 " " " "
Mock-immunized control macaques for 1st challenge
34 Ad5hr vector
only
MPL-SE only SIVmac251 SIVmac251
39 " " " "
Naïve Macaques for 2nd challenge
160 None None None SIVmac251
173 " " "
a Each Ad5hr-SIV recombinant was administered at a dose of 5 × 108 pfu. The
total Ad5hr dose was made up to 1.5 × 109 with the empty Ad5hr vector when
the immunization mixture contained fewer than three recombinants. The week 0
immunization was intranasal; the week 12 intratracheal.
b Envelope subunits (100 μg/dose) were administered intramuscularly.
c The second IR challenge was given 53 weeks after the first with no
intervening immunization.
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humoral, cellular, and mucosal immune responses (Buge et
al., 1997, 1999; Lubeck et al., 1997; Malkevitch et al., 2003;
Patterson et al., 2003; Peng et al., 2005; Pinczewski et al.,
2005; Zhao et al., 2003a; Zolla-Pazner et al., 1998).
Protective efficacy has been demonstrated in chimpanzees
against low- and high-dose HIV challenges, including
challenge with a primary isolate heterologous to the vaccine
strain (Lubeck et al., 1997; Robert-Guroff et al., 1998). In
macaques, decreased acute viremia following intravaginal
challenge with virulent SIVmac251 resulted from a vaccine
regimen using only an Ad-SIVenv recombinant and gp120
boosting (Buge et al., 1997). A greater degree of protection
against an intrarectal SIVmac251 challenge was achieved with
the addition of an Ad-SIVgag recombinant to the immuni-
zation strategy (Zhao et al., 2003b). Most recently, we
reported that two sequential immunizations with Ad type 5
host-range mutant (Ad5hr)-SIV multigene recombinants
encoding SIVenv/rev, gag, and/or nef, followed by two
envelope subunit boosts elicited potent, persistent cellular
and humoral immunity (Malkevitch et al., 2003; Patterson et
al., 2003) that lasted more than 30 weeks. Following
SIVmac251 challenge, decreased acute viremia was associated
with anti-envelope binding antibodies, and decreased chronic
phase viremia with SIV-specific cellular immune responses to
Env and Rev (Patterson et al., 2004). Although we were not
able to demonstrate neutralization of primary SIVmac251 by
sera obtained from the vaccinated macaques at the time of
challenge, antibodies present in the sera mediated potent
antibody-dependent cellular cytotoxicity (ADCC). Antibody
titers mediating ADCC were correlated with reduced acute
viral burdens (Gómez-Román et al., 2005). The striking result
of this study was the subset of macaques (39%) that exhibited
remarkably strong protection, either showing no viremia,
clearing viremia, or controlling viremia at the threshold of
detection (Patterson et al., 2004).
One rationale for choice of a replicating vaccine vector is its
potential for eliciting long-lasting protection. Therefore, in the
present work, we addressed this point and evaluated the
durability of protection in the subset of immunized, highly
protected macaques by administering a second pathogenic
SIVmac251 rectal challenge 1 year after the first challenge with
no intervening immunizations. Two SIV-infected, unimmu-
nized macaques and 2 naïve control macaques were included
in the study. We systematically monitored immune responses
in the monkeys before and after the rectal challenge. Strong,
durable protection was seen in 8 of 11 vaccinees associated
with a high level of SIV-specific IFN-γ-secreting cells
primarily to Gag and elevated lymphoproliferative responses
to p27 prior to re-challenge compared to the naïve and
unimmunized viremic animals. Subsequent in vivo depletion
of CD8+ T cells of the 8 durably protected macaques together
with careful monitoring of SIV-specific immune responses
suggested a protective role of SIV-specific CD8+ T cells,
although a contribution of NK or NKT cells to this protection
cannot be excluded. SIV-specific antibodies, although present,
were not correlated with protection from the second SIVmac251intrarectal challenge. Our study demonstrates that the vaccine
regimen performed as desired by eliciting potent, SIV-specific
CD8+ T lymphocytes that initially contained chronic viral
burdens following the first SIVmac251 challenge (Patterson et
al., 2004). This cellular immunity, perhaps augmented by
immune responses resulting from subsequent low-level or
inapparent SIV infection, led to long-term effective control
and/or clearance of viremia following the second viral
challenge.
Results
Durable protection in immunized macaques after a second
SIVmac251 challenge
As previously reported (Patterson et al., 2004), a vaccine
regimen composed of priming with two or more Ad5hr-SIV
recombinants and boosting with SIVgp120 or priming with
Ad5hr-SIVenv/rev and boosting with an SIV polypeptide
(termed “peptomer”) representing the CD4 binding region of
the SIV envelope, resulted in strong protection in 12 of 31
Fig. 1. Viral burdens in immunized and control macaques following rectal
SIVmac251 challenges at weeks 0 and 53. (A) Immunized macaques exhibiting no
detectable viremia following the first challenge. (B) Immunized macaques that
cleared viremia or strongly controlled viremia at the threshold of detection
following the first challenge. (C) Immunized macaques that controlled viremia
with fluctuations around the detection threshold following the first challenge.
(D) Control macaques from the first challenge experiment including two (#34
and #39) that exhibited natural control by week 40 and were subsequently re-
challenged. (E) Naïve control macaques for the second SIVmac251 challenge.
Viral burdens over weeks 0 to 40 were taken from Patterson et al. (2004).
Arrows mark the SIVmac251 challenges at weeks 0 and 53. SIV RNA copies
<2000/100 μl, representing the initial detection threshold, are plotted as
10,000 copies/ml (marked by the dashed line). Undetectable SIV RNA at the
intermediate sensitivity of <500 copies/input volume (1 or 0.5 ml) is plotted as
500 or 103 copies/ml respectively. Undetectable SIV RNA at <50 copies/input
volume is plotted as 50 copies/ml.
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received are summarized in Table 1. The strong protection in the
12 macaques following the first intrarectal SIVmac251 challenge
was defined by their viral burdens, determined at three levels of
sensitivity as detailed in Materials and methods: a routine
nucleic acid sequence-based assay (NASBA) with a threshold
level of <2000 SIV RNA copies/100 μl plasma; an intermediate
assay with a detection limit of <500 copies/0.5 to 1 ml plasma,
and a real-time assay with a sensitivity of <50 copies/0.5 to 1 ml
plasma. As detailed in our previous report, four macaques had
no detectable plasma viremia at the intermediate level (Fig. 1A)
for the entire 40-week observation period, although SIV
proviral DNA was detected on at least one occasion in plasma
of each macaque post-challenge (Patterson et al., 2004). Four
macaques cleared viremia below the intermediate level or
strongly controlled viremia at the threshold level of detection by
8 weeks post-challenge (Fig. 1B). Four others controlled
viremia by 8 to 12 weeks post-challenge with repeated
fluctuations around the detection threshold (Fig. 1C). In
contrast, eight mock-immunized control macaques exhibited
high viral burdens post-challenge, except for two whose viremia
declined to the detection threshold by 40 weeks post-challenge
(Fig. 1D).
Protection in the immunized macaques compared to the
controls was also evident by their CD4 counts in peripheral
blood. Following the first intrarectal challenge, all 12
immunized macaques maintained CD4 counts above 200/mm3
(Figs. 2A–C). In contrast, the mock-immunized controls
displayed gradual depletion of CD4 cells to below 200/mm3
except for macaque #39 that exhibited gradual viremia control
and maintained CD4 cell counts above 200 until after the re-
challenge (Fig. 2D). Three of the mock-immunized controls
were euthanized due to AIDS within a year of the first
challenge. Three others were lost to follow-up after transfer to
another investigator for therapy studies. Macaques #34 and #39
were maintained for further study.
To evaluate the durability of protection, one year (week 53)
after the first SIVmac251 intrarectal challenge, eleven of the
original strongly protected vaccinees were re-challenged
rectally with the same SIVmac251 stock. Mock-immunized
control macaques #34 and #39 were also re-challenged in
order to compare responses of the vaccinees with macaques that
exhibited some natural control of viremia. Two naïve macaques
served as controls for the challenge stock. Administration of the
second SIVmac251 rectal challenge resulted in high viral burdens
in the naïve macaques #160 and #173 (Fig. 1E). Acute viremia
rose to over 1 × 108 SIV RNA copies/ml of plasma. At week 20,
macaque #160 died of AIDS-related complications while the
CD4 counts of macaque 173 dropped below 200/mm3 (Fig. 2E).
The unimmunized, chronically SIV-infected monkeys, #34 and
#39, exhibited viremia around the detection threshold after the
second SIVmac251 challenge (Fig. 1D), while their CD4 cells
remained at or below 200/mm3 (Fig. 2D).
Following administration of the second SIVmac251 challenge,
three of the eleven previously protected monkeys exhibited
sustained viremia above the detection threshold: #41, #4, and
#40 (Figs. 1A, C), although up to a 3 log decrease in viral load
Fig. 2. Peripheral blood CD4+ Tcell counts in immunized and control macaques
following rectal SIVmac251 challenges at weeks 0 and 53. (A) Immunized
macaques exhibiting no detectable viremia following the first challenge. (B)
Immunized macaques that cleared viremia or strongly controlled viremia at the
threshold of detection following the first challenge. (C) Immunized macaques
that controlled viremia with fluctuations around the detection threshold
following the first challenge. (D) Control macaques from the first challenge
experiment including two (#34 and #39) that exhibited natural control by week
40 and were subsequently re-challenged. (E) Naïve control macaques for the
second SIVmac251 challenge. Arrows mark the SIVmac251 challenges at weeks 0
and 53. The dashed line is placed at the level of 200 CD4+ T cells/mm3 blood.
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Further, only one of these three, macaque #4, exhibited a
sustained drop in CD4 cell numbers to approximately 200/mm3(Fig. 2C), while macaques #40 and #41 exhibited only a
transient decline in CD4 cell number which then rebounded
(Figs. 2A, C).
In contrast to the modest viremia seen in these 3
immunized macaques, the eight other previously protected
vaccinees remained strongly protected after the second
challenge, with viral loads occasionally fluctuating above
500 SIV RNA copies/ml, but always remaining <20,000
copies/ml plasma (Figs. 1A–C). Three of these macaques, #5,
#7, and #9, exhibited no plasma viral RNA at all in the
intermediate assay, and therefore, where available, their
plasma was assessed in the real-time assay with the greatest
detection sensitivity. Macaques #7 and #9 again consistently
exhibited undetectable viremia (<50 SIV RNA copies; Fig.
1A), as did macaque #5 except for a single time point with
SIV RNA at the 500 copy level (Fig. 1B). In accordance with
the strong control of SIV replication, all eight durably
protected macaques maintained strong preservation of CD4+
T cell numbers (Figs. 2A–C). Overall, ten of eleven of the
original strongly protected, immunized macaques maintained
CD4 T cell counts >200/mm3.
Cellular immune responses prior to re-challenge correlate with
viremia control in durably protected macaques
To investigate a possible correlation between vaccine-
induced immunity and control of viremia in the durably
protected macaques, we performed a systematic evaluation of
SIV-specific immune responses in all animals before and after
the second SIVmac251 challenge, beginning with cellular
immunity. Secretion of IFN-γ by PBMC in response to
Env, Gag, Nef, and Rev peptide pools was evaluated by
ELISPOT. Thirty days prior to the second challenge the
protected group of eight macaques demonstrated a higher
number of IFN-γ-secreting cells across all four peptides
compared to immunized, viremic (P = 0.037), SIV-infected,
unimmunized (P = 0.05), and naïve (P = 0.01) macaques
(Table 2). The predominant response among the protected
macaques was to Gag peptides, although Env peptides were
well recognized in all but the naïve macaques. Following re-
challenge, we did not observe a statistically significant
difference in the number of IFN-γ-secreting cells to any of
the peptide pools between the durably protected and any of
the other macaque groups, although responses to Gag peptides
in the protected group were somewhat higher at weeks 2, 5,
and 8 (data not shown).
We also evaluated T cell proliferative responses to SIV
gp120, Ald-SIV, SIV p27, and Nef before and after the second
challenge (Table 2). Prior to the re-challenge, the protected
group exhibited significantly higher proliferative responses to
p27 compared to the immunized, viremic group (P = 0.026) but
not compared to the SIV-infected unimmunized macaque #39.
Similarly to the ELISPOT results, no significant differences
were seen following re-challenge. Proliferative responses to
gp120, Ald-SIVand Nef were generally low or negative, and no
significant differences were observed among the groups of
macaques before or after re-challenge.
Table 2
Cellular immune responses 30 days prior to SIVmac251 re-challenge
Macaque ELISPOT Proliferation
(SFC/106 PBMC) (Stimulation index)
Gag Env Nef Rev gp120 Ald-SIV p27 Nef
Naïve control
160 0 0 0 0 nd nd nd nd
173 0 0 0 0 nd nd nd nd
Mean ± SEM 0 0 0 0
Unimmunized, SIV-infected
34 0 0 0 0 nd nd nd nd
39 26 159 36 0 1.1 3.2 7.6 1.4
Mean ± SEM 13 ± 13 80 ± 80 18 ± 18 0 1.1 3.2 7.6 1.4
Durably protected
5 574 68 0 0 1.4 4.4 1.9 0.3
7 38 0 0 0 2.6 0.7 2.0 0.8
9 336 52 177 0 0.8 0.3 0 0
15 48 0 0 0 2.7 0.03 7.9 1.1
28 57 13 87 0 4.1 0.04 22.3 1.9
29 572 0 51 0 1.7 0.03 0.04 3.4
32 286 0 0 0 2.7 0.03 7.9 1.1
33 0 321 0 0 3.9 0.01 23.9 0.5
Mean ± SEM 239 ± 85 a 57 ± 39 a 39 ± 23 a 0 a 2.4 ± 0.4 0.7 ± 0.5 7.3 ± 3.6 b 1.2 ± 0.4
Immunized, viremic
4 0 0 0 0 1.3 0.06 0.1 1.2
40 0 433 38 35 3.0 0.03 0.8 0.5
41 23 0 0 0 3.1 0.7 0 0.5
Mean ± SEM 8 ± 8 144 ± 144 13 ± 13 12 ± 12 2.4 ± 0.6 0.3 ± 0.2 0.3 ± 0.2 b 0.7 ± 0.2
Macaques are grouped as durably protected (eight original immunized, protected macaques that exhibited durable protection following re-challenge); immunized,
viremic (three immunized, previously protected macaques that became viremic following re-challenge); SIV-infected, unimmunized (two original unimmunized
control macaques that gradually controlled viremia by week 40 after the first challenge); and naïve (two macaque controls for the SIVmac251 re-challenge).
nd = Not determined as viable PBMC were not available for the two naïve macaques nor for macaque #34 in the SIV-infected, unimmunized group.
a The durably protected macaques exhibited a higher number of IFN-γ-secreting cells across all four peptides compared to the immunized viremic (P = 0.037),
SIV-infected, unimmunized (P = 0.05), and naïve (P = 0.01).
b The durably protected macaques exhibited higher proliferative responses to p27 compared to the immunized viremic macaques (P = 0.026).
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against re-challenge
In our previous work, we demonstrated a significant
negative correlation between acute viremia and serum binding
antibodies to envelope following the initial intrarectal
challenge with SIVmac251 (Patterson et al., 2004). These
binding antibodies were subsequently shown to mediate
ADCC activity that was significantly correlated with the
reduced acute-phase viremia (Gómez-Román et al., 2005).
Therefore, we examined anti-SIV envelope antibodies in serum
and mucosal secretions in order to evaluate humoral immunity
as a possible mechanism of durable protection. Table 3
summarizes the results of assays evaluating both binding
antibodies and functional antibodies mediating neutralization
and ADCC activity. In general, serum antibody responses did
not correlate with protection against the SIVmac251 re-
challenge. Two of the durably protected macaques, #7 and
#9, exhibited little anti-envelope binding, neutralizing or
ADCC antibodies at the time of re-challenge. These macaques
had been boosted with the SIV peptomer and never developed
strong antibodies to SIV gp120 (Patterson et al., 2004). Asthey also were aviremic following the initial SIVmac251
challenge, they did not develop anti-envelope antibodies
attributable to SIV infection. Note that macaque #5, similarly
immunized, did exhibit anti-envelope antibody responses, as a
result of both the earlier Ad5hr-SIVenv/rev priming immuniza-
tions and transient virus exposure following the initial
challenge. Binding antibody titers were already high in all
the remaining immunized and unimmunized SIV-infected
macaques (Table 3); therefore anamnestic antibody responses
following re-challenge were not observed except in macaque
#41 (data not shown), reflecting the rapid infection and
viremia increase in this macaque. Although neutralizing
antibodies to T-cell-line-adapted SIVmac251 were present,
none of the macaque sera neutralized primary SIVmac251 in
an infectivity reduction assay. Antibodies mediating ADCC
were readily detected in all but the naïve macaques and
macaques #7 and #9, but again did not correlate with
protective outcome post-re-challenge.
Mucosal anti-envelope binding antibodies were also evalu-
ated in rectal secretions and saliva. SIV-specific IgA antibodies
were not observed either before or after the SIVmac251 re-
challenge (data not shown). Anti-SIVgp120 IgG antibodies
Table 3
Antibodies to SIV envelope at the time of re-challenge in sera and mucosal secretions
Macaque Binding
titer to
SIV gp120
Neutralizing
antibody
titer a
ADCC mediating titer Rectal IgG (O.D.) Salivary IgG (O.D.)
H9/SIV
targets
CEM.NKr/gp120
targets
Pre-re-
challenge b
Anamnestic
response c
Pre-re-
challenge b
Anamnestic
response c
Naïve control
160 <10 <10 <100 <100 0.11 0.30 0.19 0.19
173 <10 25 100 100 0.13 0.17 0.14 0.29
Unimmunized, SIV-infected
34 1.9 × 106 1.4 × 104 1 × 107 1 × 106 0.65 0.87 1.25 1.37
39 12.3 × 106 2.2 × 104 >1 × 107 1 × 107 0.08 1.24 1.55 1.46
Durably protected
5 1.7 × 105 3.2 × 103 1 × 105 1 × 105 0.08 0.09 0.31 0.50
7 7.5 × 101 <10 <100 <100 0.11 0.11 0.12 0.53
9 <10 <10 <100 <100 0.08 0.09 0.11 0.11
15 6.4 × 105 1.8 × 104 1 × 106 1 × 106 0.21 0.30 0.58 1.06
28 5.1 × 105 1.6 × 104 1 × 106 1 × 106 0.16 0.17 1.10 1.08
29 1.1 × 105 2.0 × 104 1 × 105 1 × 106 0.26 0.65 1.86 1.80
32 1.5 × 105 1.1 × 104 1 × 105 1 × 106 0.30 0.21 1.12 1.02
33 1.7 × 105 2.1 × 104 1 × 105 1 × 106 0.22 0.20 1.11 1.53
Immunized, viremic
4 3.0 × 105 2.3 × 104 1 × 106 1 × 106 0.11 0.15 0.74 1.25
40 2.0 × 106 4.2 × 104 >1 × 107 1 × 107 1.32 1.86 1.98 2.21
41 2.3 × 104 1.5 × 103 1 × 104 1 × 106 0.15 0.16 0.29 0.64
a Neutralizing antibody against TCLA-SIVmac251. All sera were negative (<10-fold decrease in viral infectivity) for neutralization of primary SIVmac251 in an
infectivity reduction assay.
b Positive IgG response in bold defined as equal to or greater than two times the mean O.D. of the naïve control macaques.
c Positive anamnestic response in bold defined as equal to or greater than two times the pre-re-challenge O.D. value.
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secretions, but more frequently in saliva (Table 3). This may
reflect the greater dilution of the rectal samples tested (1:100)
compared to the dilution of saliva (1:10). Anamnestic responses
following the re-challenge were also rarely observed. Overall,
there was no correlation of SIV-specific mucosal binding
antibody with durability of protection.
In vivo CD8+ T lymphocyte depletion of durably protected
macaques
Evaluations of immune responses following the re-challenge
suggested an important role of SIV-specific CD8+ T lympho-
cytes in conferring durable protection against pathogenic
SIVmac251. Therefore, 9 months after the second challenge, we
depleted CD8+ T cells in vivo from the eight durably protected
macaques and one SIV-infected unimmunized monkey, #39, in
order to confirm the involvement of CD8+ T cells in
containment of SIV replication. An additional SIV-infected
unimmunized monkey, #34, was given an IgG isotype control
antibody in order to demonstrate that any subsequent change in
viremia level or immune response was due to CD8+ T cell
depletion rather than to IgG itself.
Administration of 3 injections of antibody cM-T807 to
macaques depleted 97–99% of CD8+ T cells from peripheral
blood for a period of about 10 days (Fig. 3). Concomitant with
CD8 depletion, the macaques exhibited a rapid emergence ofviremia, ranging from 105 to 108 SIV RNA copies/ml plasma
(Fig. 3). As CD8+ T cells reappeared in the blood around day
21, viral replication was brought under control. Of interest,
CD8 depletion in macaques #7 and #9 was not associated with
emergence of viremia. In fact, at all time points, viremia in
these macaques was <50 SIV RNA copies/ml plasma (Fig. 3).
The subset of CD4+ T cells was relatively stable during the
course of CD8 depletion (data not shown). A transient
reduction was observed at day 3 post-depletion. Thereafter,
CD4 counts remained at predepletion levels until approximate-
ly day 21 when counts exhibited a modest rise as viremia was
controlled. The SIV-infected, unimmunized macaque #39
showed elevated viremia during CD8 depletion, however, in
contrast to the durably protected macaques, when CD8+ T cells
were restored the viral load was not contained (Fig. 3).
Macaque #34 exhibited slight fluctuations of CD8+ T cells and
viral load after IgG isotype administration (Fig. 3). Such
fluctuations are not unusual, as has been described by others
(Schmitz et al., 1999a).
Because SIV infects tissue lymphocytes as well as PBL, we
monitored CD8+ T cell levels and the level of SIV RNA in
lymph node (LN) and rectal tissue biopsies before and after
administration of the cM-T807 antibody. Thirty days prior to
depletion of CD8+ T cells SIV RNAwas not detected in rectal
tissues of either the protected macaques or the chronically SIV-
infected monkeys (Table 4) although adequate target cells for
viral infection were present. CD3+/CD4+ T cells in rectal tissue
Fig. 3. In vivo depletion of CD8+ Tcells and associated changes in SIV plasma viremia. The 8 durably protected macaques (numbers 5, 7, 9, 15, 28, 29, 32, and 33) are
presented in separate panels, along with one unimmunized, SIV-infected macaque (#39), and one unimmunized, SIV-infected macaque (#34) that received the isotype
control antibody, synagis. The cM-T807 antibody or control antibody was administered to the macaques on days 0, 3, and 7, as described in Materials and methods.
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28.2% in the unimmunized, SIV-infected macaques #34 and
#39, respectively, and ranged from 29.1% to 68.9% in the
durably protected macaques. Lymph node CD3+/CD4+ T cells
prior to CD8+ T cell depletion were 47.3% and 44.3% in
macaques #34 and #39, respectively, and ranged from 47.7% to
67.9% in the durably protected animals. After administration of
anti-CD8 antibody, on average only 37% of CD8 T cells were
depleted from rectal tissue. It has been shown, however, that
binding of cM-T807 to CD8+ T cells diminishes their function
(Schmitz et al., 1999b), so loss of CD8+ T cell activity might
have been greater than suggested by the level of depletion.
Overall, the antibody treatment resulted in emergence of
detectable virus in rectal samples from the unimmunized,
SIV-infected macaque, #39, and from all the durably protected
macaques except #7 and #9. Viral burdens ranged from 1 × 104
to 4 × 106. Virus did not emerge in the unimmunized SIV-
infected macaque (#34) treated with the control synagis
antibody. With restoration of CD8 T cells, all macaques but
two regained viremia control. The two exceptions, #5 and #33,
had exhibited the highest viral burdens in rectal tissue at day 13
(>106 copies/μg RNA) but were able to reduce the viral load 3
logs by day 64.
In contrast to rectal tissue, administration of the anti-CD8
antibody depleted a higher proportion of CD8+ T cells from
LN, on average 87%. Unfortunately, analysis of SIV RNA in
LN was not possible in all macaques, as sufficient RNA couldnot always be extracted from the biopsies. Of the samples
analyzed, 4 of 6 durably protected macaques and the two
unimmunized, SIV-infected macaques exhibited SIV RNA
prior to depletion, with somewhat lower copy numbers seen in
the protected animals (Table 4). At the time of peak CD8
depletion, viral burdens were elevated in the LN biopsies of
three of the four protected macaques able to be analyzed.
However, viral loads were not significantly decreased with
restoration of T cell numbers but remained similar to levels seen
prior to or during CD8 depletion. Overall, CD8 depletion and
restoration did not coincide with emergence and control of virus
in LN as was seen in rectal tissue. Of interest, tissues of
macaques #7 and #9 were negative for SIV RNA at all time
points that could be analyzed.
Anti-SIV immunity during CD8 depletion
ELISPOT responses in PBMC to Env, Gag, Nef and Rev
peptide pools were evaluated prior to, during, and after CD8
depletion. Before depletion, the durably protected macaques
demonstrated a dominant cellular response to Env peptides and
modest responses to Gag, Nef, and Rev peptide pools (Fig. 4A).
Between days 7 and 13, the time of greatest CD8+ T cell
depletion, responses to Env, Nef, and Rev were markedly
decreased. Responses to Gag peptides, however, showed little
change over time, perhaps reflecting significant numbers of SIV
Gag-specific CD4+ T cells in the PBMC. To evaluate this
Table 4
Viral loads and level of CD8+ T cells in rectal tissue and lymph nodes before and after CD8 depletion
Tissue Macaque SIV copies/μg RNA %CD3+/CD8+ T cells
−30 days Day 13 Day 64 −30 days Day 13 Day 64
Rectal tissue Durably protected
#5 <500 1.0 × 106 3.6 × 103 46.7 8.5 28.1
#7 <500 <500 <500 30.5 12.3 24.8
#9 <500 <500 <500 58.1 21.4 30.0
#15 <500 1.3 × 104 <500 73.1 52.0 43.3
#28 <500 3.1 × 104 <500 56.7 37.8 34.2
#29 <500 5.8 × 105 <500 60.5 49.3 50.6
#32 <500 5.0 × 105 <500 52.0 50.7 30.0
#33 <500 4.0 × 106 1.4 × 103 42.3 37.2 40.0
Unimmunized, SIV infected
#39 <500 8.6 × 103 <500 70.8 47.6 57.4
#34 (Synagis) <500 <500 <500 79.4 88.4 57.3
Lymph node Durably protected
#5 3.9 × 104 nd 4.1 × 105 31.3 3.3 14.9
#7 nd nd <500 31.4 1.4 9.6
#9 <500 <500 <500 19.3 0.7 7.6
#15 nd nd 7.4 × 104 32.6 11.8 28.6
#28 <500 7.4 × 103 1.3 × 105 30.2 7.9 26.2
#29 9.8 × 104 1.0 × 106 2.1 × 105 28.8 0.8 19.2
#32 2.9 × 104 nd 2.1 × 104 24.8 2.9 16.8
#33 5.0 × 104 2.0 × 105 nd 32.0 2.8 17.1
Unimmunized, SIV infected
#39 2.1 × 105 6.8 × 105 5.5 × 105 35.0 5.5 26.8
#34 (Synagis) 3.2 × 105 8.4 × 104 1.3 × 105 32.8 28.4 53.7
nd = Not done, as insufficient RNA was extracted from the biopsied samples.
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on cells obtained 38 to 41 weeks following in vivo CD8
depletion from two macaques, #29 and#33, using unfractio-
nated PBMC and PBMC depleted of either CD4 or CD8 cells in
vitro. Both macaques exhibited abundant numbers of IFN-γ-
secreting cells when CD8 cells were depleted but decreased
numbers of IFN-γ-secreting cells (approximately 36% of the
unfractionated PBMC response) when CD4 cells were depleted
(data not shown). Although we do not know that this CD4
response was also present during the time of the greatest CD8
depletion, the result obtained suggests the persistent presence of
SIV Gag-specific CD4+ T cells in at least these two macaques.
Overall, the re-appearance of CD8+ T lymphocytes and
containment of viremia beginning at day 21 post in vivo CD8
depletion coincided with higher numbers of IFN-γ-secreting
cells to Env, Gag, Nef, and Rev peptides (Fig. 4A).
In contrast to the immunized, durably protected macaques,
the SIV-infected, unimmunized macaque #39 exhibited many
fewer IFN-γ-secreting cells in response to Env, Gag, Nef, and
Rev peptides over the course of CD8 depletion (Fig. 4B). This
result illustrates a difference in level of immune response of the
durably protected macaques that exhibit potent, persistent
immunity elicited by the vaccine regimen in comparison to
that induced by natural SIV infection, although a firm
conclusion cannot be made based on this single animal.
We also measured antigen-specific lymphoproliferative
responses of PBMC to gp120, Ald-SIV, p27, and Nef proteins
before and after CD8 depletion. Thirty days prior to depletion,
the protected group exhibited strong proliferative responses togp120, Ald-SIV, and p27 (Fig. 4C). These responses fluctuated
but were maintained throughout the CD8 depletion period. In
contrast, the SIV-infected, unimmunized macaque, #39, had
diminished CD4+ T cell counts (see Fig. 2D) and proliferative
responses remained low at all time points (Fig. 4D). These
findings again suggest a vaccine effect on the persistence of
anti-SIV immunity, although evaluation of more SIV-infected
unimmunized macaques would be needed to prove the point.
It was also of interest to evaluate immune responses of cells
in tissue compartments before and at days 13 and 64 after
depletion. Because cell numbers were limited, we performed
IFN-γ ICS on fresh cells from LN biopsies and rectal pinches
in response to mixed SIV Env, Gag, and Nef peptide
stimulation (Fig. 5). Thirty days prior to depletion, immune
responses were not detected in LN, however, at day 13 in spite
of the overall 87% depletion of CD8+ lymphocytes, IFN-γ-
secreting cells increased to 0.25% of the remaining CD8+ T
cells, suggesting a rapid response to the emergence of virus.
These cells persisted and underwent further expansion by day
64 when the SIV-specific IFN-γ-secreting CD8+ T cell
population reached 1.3%. Rectal tissue already exhibited a
positive IFN-γ response to the mixed peptide stimuli prior to
CD8 depletion. CD8 T cell numbers sufficient for analysis were
not recovered at day 13 following administration of the cM-
T807 antibody. However, as the CD8 T cell population was
restored, SIV-specific IFN-γ-secreting cells reappeared robust-
ly to a level of 3.8% (Fig. 5). This increased response at day 64
post-depletion in rectal tissue was associated with containment
of localized virus (Table 4).
Fig. 4. Cellular immune responses observed before and after in vivo CD8 depletion. ELISPOT responses to SIV peptide pools over the course of depletion are shown
for the durably protected macaques (A) and the unimmunized, SIV-infected macaque #39 (B). The peptide pools are indicated as E, G, N, and R, representing Env,
Gag, Nef, and Rev, respectively. T cell proliferation responses to SIV proteins are shown in the durably protected macaques (C) and the unimmunized, SIV-infected
macaque #39 (D) before and after CD8 depletion. The antigenic stimuli for the proliferative responses are indicated under each box plot. i-SIV = aldrithiol-inactivated
SIV. The box plots include median values and 5 and 95% percentiles for the durably protected macaques.
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macaques #7 and #9
From the time of initial SIVmac251 infection at day 0,
throughout re-challenge with SIVmac251 at week 53 andFig. 5. Intracellular staining of CD8+ IFN-γ+ T cells in lymph nodes and rectal
tissue in response to stimulation with a mixture of SIV Env, Gag, and Nef
peptides before and after CD8 depletion. The numbers of tissue biopsies tested
are indicated above each bar. At day 13 post-depletion, the number of CD8 T
cells in rectal tissue was insufficient for analysis.subsequent in vivo CD8 depletion, durably protected maca-
ques #7 and #9 never showed any detectable viremia, even
following the effective depletion of CD8+ T lymphocytes. We
previously reported that these macaques exhibited occasional
provirus positivity, indicating that they did not have
“sterilizing” immunity (Patterson et al., 2004). To elucidate
possible immunologic mechanisms associated with their
remarkably strong, durable protection, a detailed summary of
their immune responses pre- and post-re-challenge and CD8
depletion is presented in Table 5. Macaque #7 exhibited
positive proliferative responses to both SIV Gag and envelope
proteins before and after the SIVmac251 re-challenge, respec-
tively, as well as a stronger proliferative response to SIV
gp120 and a potent response to SIVp27 before in vivo CD8
depletion that may have contributed to the protective outcome.
While the ELISPOT responses of macaque #7 were low or
undetectable at the times of re-challenge and in vivo CD8
depletion, the numbers of IFN-γ-secreting cells in response to
Env peptide stimulation were increased after the re-challenge,
and responses to all 4 peptide pools were elevated following
CD8 depletion. These results suggest not only the presence of
memory cells able to respond to the challenge virus but also
Table 5
SIV-specific immune responses of macaques #7 and #9 pre- and post-re-challenge and CD8 depletion
ELISPOT (SFC/106 PBMC) T cell proliferation (Stimulation index) Env binding antibodies
Env Gag Nef Rev gp120 Ald-SIV p27 Serum
(Titer)
Rectal
IgG/IgA
Salivary
IgG/IgA
Macaque #7
Pre-re-challenge a 0 38 0 0 2.6 neg 2.0 75 neg neg
Post-re-challenge b 31 0 0 0 3.5 3.3 2.0 115 neg Pos IgG
Pre-CD8 depletion c 0 0 0 0 4.1 neg 18.2 neg nd nd
Post-CD8 depletion b 230 17 135 235 neg neg neg neg nd nd
Macaque #9
Pre-re-challenge a 52 336 177 0 neg neg neg neg neg neg
Post-re-challenge b 314 224 80 20 neg 2.0 neg 165 neg neg
Pre-CD8 depletion c 336 12 103 0 neg neg 2.1 75 nd nd
Post-CD8 depletion b 621 577 136 62 5.4 neg 8.9 75 nd nd
Pos IgG = positive for IgG antibody.
a Responses were evaluated 30 days before re-challenge.
b Peak responses following re-challenge over weeks 1 to16 and CD8 depletion over days 7 to 93 are recorded.
c Responses were evaluated 30 days before CD8 depletion.
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when CD8 cells were depleted, and to which the macaque
responded. In contrast to macaque #7, macaque #9 exhibited
relatively poor proliferative responses but strong ELISPOT
responses to the SIV peptide pools. The absence of significant
mucosal antibody responses to SIV envelope and detection of
only low level serum anti-envelope binding antibodies suggest
a strong role played by cellular immune responses in
controlling viral infection in these macaques. It must be
pointed out, however, that boosting with the SIV peptomer
may have elicited antibodies recognizing unique conforma-
tional epitopes of the viral envelope not represented in the
monomeric gp120 used in the ELISA evaluations. The
possibility that such antibodies exist is undergoing further
investigation.Fig. 6. In vitro SIVmac251 infection of PBMC from macaques #7, #9 obtained
prior to immunization and of naïve macaques, #058, #E196, and #G79.
Supernatants were harvested from the cultures at the indicated days and SIV p27
was quantified by antigen capture assay. Results from the last limiting viral
dilution (1:125) at which cells of all macaques were infected are plotted. The
SIVmac251 stock used for infection contained 17.5 ng/ml p27.The strong protection of macaques #7 and #9 against the
highly virulent SIVmac251, manifested by undetectable viremia
in peripheral blood, LN and rectal tissue, suggested that they
might be resistant to SIV infection. Mamu-A*01 and Mamu-
B*17 positive macaques have been shown to be more resistant
to SIV infection compared to macaques of other MHC class I
types (Muhl et al., 2002; O'Connor et al., 2003; Pal et al., 2002),
however, neither macaque #7 nor #9 was positive for either of
these alleles. Nevertheless, other host resistance factors might
be operative in these animals. To address this question, we
assessed the ability of viably frozen PBMC of macaques #7 and
#9 obtained prior to Ad5hr-SIV recombinant immunization to
be infected by SIV in vitro. The PBMC of 3 naïve macaques,
used as positive controls, were readily infected by SIVmac251
(Fig. 6). The PBMC of macaques #7 and #9 exhibited
productive infection with slightly delayed kinetics compared
to naïve control #E196, but their rate and level of infection were
comparable to the other controls, #058 and #G79. Thus, if
macaques #7 and #9 are unusually resistant to SIV infection, it
must be attributable to an in vivo mechanism rather than to
innate host resistance.
Discussion
An effective AIDS vaccine will need to protect against
multiple HIV exposures. In the present long-term study, we
demonstrate for the first time remarkably strong protection
against two sequential pathogenic SIVmac251 rectal challenges in
macaques primed with replicating Ad5hr-SIV recombinant
vaccines and boosted with SIV envelope subunits. Previously,
such strong protection was achieved only by live-attenuated SIV
vaccination (Connor et al., 1998; Daniel et al., 1992). In the first
phase of this experiment, following an initial SIVmac251
intrarectal challenge 39% (12/31) of immunized macaques
exhibited potent protection (Patterson et al., 2004). Now we
report durable protection in 73% (8/11) of this earlier subset after
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immunizations.
Immune mechanisms of this durable protection were
investigated. Prior to the re-challenge, ELISPOT responses
across the SIV peptide pools evaluated were significantly
elevated in the immunized, durably protected macaques
compared to the other macaques studied. In addition, the
durably protected monkeys exhibited a significantly elevated
lymphoproliferative response to Gag before the re-challenge
compared to macaques in the other groups. Thus we conclude
that the durable protection was associated with potent anti-SIV
cellular immune responses. These results are in concert with our
previous findings that correlated reduced viremia at set point
with SIV Env- and Rev-specific cellular immune responses
prior to the first SIVmac251 challenge (Patterson et al., 2004).
Yet, this cellular immunity was also in part attributable to the
undetectable or low-level persistent SIV infection established
following initial SIVmac251 challenge in the protected macaques
that quickly controlled viremia. For example, cellular responses
to Gag were especially prominent at the time of re-challenge,
yet not all the animals were immunized with the Ad5hr-SIVgag
recombinant (Table 1).
In contrast to the association with cellular immunity, there
was no correlation of binding, neutralizing, or ADCC-
mediating antibody responses with protective outcome follow-
ing the re-challenge. In fact, antibodies able to neutralize
primary SIVmac251 were not detected in any of the macaques. In
general, the SIV-infected, unimmunized macaques exhibited
binding and ADCC-mediating antibodies with somewhat higher
titer compared to the immunized macaques, reflecting the
higher viral loads in these animals.
To confirm the role of SIV-specific CD8+ T cells in
protection against SIVmac251, the eight durably protected
vaccinees were depleted of CD8 T cells in vivo. The coincident
increase in viral load with CD8 depletion in all macaques except
#7 and #9 agrees with similar reports illustrating the role of CD8
T cells in controlling viral replication in infected macaques and
following immunization and challenge with SIV or SHIV
isolates (Jin et al., 1999; Matano et al., 1998; Metzner et al.,
2000; Schmitz et al., 1999a). The re-appearance of CD8+ Tcells
suppressed viral loads and enhanced IFN-γ secretion to all SIV
antigens in the eight durably protected macaques but not in the
SIV chronically infected macaque #39. Throughout the
experiment unlike the durably protected macaques, macaque
#39 never exhibited cellular immune responses to SIVantigenic
stimulation. Although statistical analysis is not possible with
only a single control macaque, this result suggests that the
vaccine regimen may have contributed to the sustained, potent T
cell responses that effectively contained SIVmac251. This
suggestion remains to be further investigated.
In these experiments, while we focused on CD3+/CD8+ T
cells, the anti-CD8 monoclonal antibody used will also deplete
those NK and NKT cells which are CD8+ (Motsinger et al.,
2003; Sandberg et al., 2002). Although control of HIV/SIV
replication mediated by these cells has not been established,
both may contribute to protective responses. NK cells have
been implicated in the protection of individuals who are highlyexposed to HIV but remain uninfected (Scott-Algara et al.,
2003). NKT cells contribute to protective immunity against a
variety of pathogens, primarily through their regulatory role in
amplifying initial innate immunity signals, thus promoting
both Th1 and Th2 responses (Taniguchi et al., 2003).
Therefore, we cannot not categorically conclude that protec-
tion was mediated only by CD8+ T cells. The contribution of
NK and NKT cells in control of HIV/SIV infection remains to
be elucidated.
CD8 depletion by the anti-CD8 monoclonal antibody was
not as effective in tissues as in peripheral blood where nearly
complete depletion was achieved. Approximately 37% of rectal
CD8 cells were depleted, and about 87% of LN CD8 cells, a bit
less than the 90 to 100% depletion reported in other studies
(Schmitz et al., 1999a, 1999b). LN CD8 depletion was
associated with slightly elevated virus loads and immune
responses, however, with restoration of CD8+ T cells, viral
burdens did not decline. The reason for lack of viral
containment is not known. It has been reported that during
chronic SIV infection the proportion of naïve CD4+ T cells and
proliferative CD4+CCR5+ memory T cells present in tissues is
critical with regard to the ability of the host to control viremia
(Picker et al., 2004). A more complete characterization of LN
cell subsets present during the in vivo depletion might have
been informative with regard to this issue.
Surprisingly in view of the known propensity for SIV to
infect CD4+CCR5+ T cells in the intestinal mucosa, while LN
were SIV positive, no SIV RNAwas detected in rectal tissue of
any of the macaques prior to CD8 depletion, including the SIV
chronically infected unimmunized macaque #39. The rectal
biopsy samples, taken 1 to 3 in. from the anus, may not have
adequately represented the entire gastrointestinal (GI) tract. SIV
is known to rapidly infect the intestinal mucosa (Li et al., 2005;
Mattapallil et al., 2005). SIV replication might be more readily
detected in biopsies of the upper GI tract obtained by
endoscopy, a procedure with some risk that can jeopardize
further studies. Evaluation of rectal pinch biopsies of highly
SIV-infected macaques could address whether the rectal sites
sampled appropriately mirror infection of the upper GI tract. As
recently reported, intestinal infection can be very localized (Li
et al., 2005; Miller et al., 2005). While virus can be easily
detected in peripheral LN during acute infection, small, discrete
founder populations at the mucosal portal of entry drive virus
replication and dissemination. Overall, in vivo CD8 depletion
was associated with marked increases in both viral load and
SIV-specific CD8+ Tcell responses in rectal tissue. Importantly,
with restoration of CD8+ cells, control of SIV was regained.
Therefore, in the highly protected macaques, CD8+ T cell
responses, perhaps including those of NK and NKT cells as
discussed above, may have contributed to local containment of
the virus at the rectal site.
The potent protection of macaques #7 and #9 at the level of
continuous, undetectable virus in PBMC, LN, and rectal tissue,
was most likely due to host immune responses, rather than
genetic factors of resistance. This conclusion is based on the
persistent cellular immune responses of the two macaques, and
the susceptibility to in vitro infection by SIVmac251 of PBMC
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challenge. Further, as noted above, macaques #7 and #9 are
negative for both the Mamu-A*01 and Mamu-B*17 alleles
associated with greater resistance to SIV infection. It was
recently reported that Mamu-A*01 negative macaques rely less
on CD8+ lymphocytes for viremia control compared to Mamu-
A*01 positive macaques, suggesting a greater role of other
immune mechanisms such as humoral immunity in containing
viremia (Schmitz et al., 2005). However, we were able to detect
only low-level anti-envelope binding antibodies in these
animals, and functional antibodies were not observed. The
elevated ELISPOT and/or lymphoproliferative responses ob-
served in PBMC of macaques #7 and #9 following re-challenge
and/or CD8 depletion despite the absence of detectable viremia
suggest on-going, low-level, but anatomically contained SIV
replication. Similar viremia control at undetectable levels
resulting from vaccination followed by low-level infection
with SHIVIIIB or by SIV infection followed by anti-retroviral
therapy has been attributed to cellular immunity induced or
maintained by inapparent viral replication (Kim et al., 2001;
Lifson et al., 2000, 2001). Such control of SIVΔB670 replication
following vaccination has been attributed to low-level viral
replication in a reservoir located in the gastric-associated
lymphoid tissue (Fuller et al., 2002). In experiments with live
attenuated SIV, it was similarly reported that minimal,
undetectable viral replication might have been sufficient to
provide antigenic stimulation and sustain potent anti-viral
cellular immunity (Connor et al., 1998). Analysis of other
anatomical compartments of macaques #7 and #9 may reveal
viral reservoirs that were not detected in peripheral blood,
inguinal lymph nodes, or rectal tissue.
Following vaccination and the initial SIVmac251 intrarectal
challenge, the 11 macaques studied here exhibited potent
protection although not sterilizing immunity (Patterson et al.,
2004). Here, in comparison to unimmunized macaques that
naturally exhibited a degree of viremia control, we demonstrate
the role of the vaccine regimen in induction of protective
cellular immunity and maintenance of persistent immune
responses, leading to durable protection manifested by low or
undetectable viremia and preservation of CD4 T cells.
Undoubtedly the low-level or unapparent infection of the
protected macaques also contributed to maintenance of the
immune response, but this process was initiated by a vaccine
regimen that established viral control at a level that could be
subsequently maintained by innate and adaptive host immune
responses. This outcome provides support for the “threshold
hypothesis” below which adequate control of SIV infection can
be maintained (Ruprecht et al., 1996). The role of cellular
immunity, including CTL activity and proliferative responses,
in controlling HIV replication is well documented (Rosenberg et
al., 1997, 1999). Studies in the SIV macaque system have
similarly demonstrated the critical role of cellular immune
responses in controlling viremia (Hel et al., 2002; Letvin et al.,
1999).
While we have demonstrated that SIV-specific T cells
contributed to durable protection against SIVmac251, we have
not elucidated specific protective mechanisms. Multiplemechanisms, including systemic and mucosal humoral and
cellular immunity and innate immune responses, are likely
involved. Given the outbred nature of study subjects, it may not
be possible to uncover single “correlates of protection” in
vaccine trials. Further, not all potential protective mechanisms
were studied here. For example, soluble factors produced by
CD8 T cells that suppress SIV infection (Cocchi et al., 1995;
Mackewicz and Levy, 1992) may have played a role but were
not investigated. Moreover, while we observed no correlation
between antibody responses and protective outcome, all but two
macaques, #7 and #9, exhibited functional SIV-specific
antibodies that may have contributed to durable protection.
The role of neutralizing antibody in mediating protection is well
established (Mascola, 2003), and antibodies mediating ADCC
have been correlated with reduced acute-phase viremia
following SIVmac251 challenge (Gómez-Román et al., 2005).
Both may have contributed to the protective outcomes seen here
following re-challenge.
Overall, the strong durable protection against pathogenic
SIVmac251 challenge observed in macaques immunized with
multigenic replication-competent Ad-SIV recombinants and
boosted with SIV envelope protein or an envelope protein
subunit supports continued development of this vaccine
approach. The potential advantage of the replication-competent
Ad vector and other replicating vaccine vectors that also can
target mucosal sites should be further investigated and exploited.
Materials and methods
Animals, re-challenge and sample collection
Eleven rhesus macaques (Macaca mulata) previously
immunized with Ad5hr recombinants encoding SIVsmH4env/
rev, SIVmac239gag and/or SIVmac239nef and boosted with native
SIVmac251 gp120 or an SIV “peptomer” (Robey et al., 1995,
1996), a polypeptide representing the CD4 binding site of
SIVmac251 gp120, were studied (Table 1). As described earlier in
detail, all eleven macaques were previously strongly protected
against a rectal SIVmac251 challenge (Patterson et al., 2004). A
twelfth macaque, #38, that had undetectable viremia following
the first SIVmac251 challenge was not available for re-challenge
due to death, unrelated to SIV challenge, following a surgical
procedure to collect biopsy samples. Two macaques (#34 and
#39) that served as controls for the initial SIVmac251 challenge
and had detectable viremia and low CD4+ T cell counts were
included to compare the protective effect of prior immunization
of the vaccinees with unimmunized macaques that gradually
controlled viremia. Two naïve control macaques (#160 and
#173) were included to monitor the infectivity of the
administered SIVmac251 challenge. Animal housing and care
were provided by Bioqual, Inc. in accordance with their Animal
Care and Use Committee guidelines. All macaques were re-
challenged intrarectally 53 weeks after the first SIVmac251
challenge with 10 animal infectious doses of pathogenic
SIVmac251. The SIVmac251 challenge stock, developed by Dr.
Ronald Desrosiers, New England National Primate Research
Center, and made available by Dr. Nancy Miller, Division of
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Peripheral blood mononuclear cells (PBMC) were purified
from blood samples obtained 30 days before and throughout the
re-challenge and CD8 depletion experiments using lymphocyte
separation medium (ICN Pharmaceuticals, Inc.). Fresh cells
were used for immunological assays. Plasma and sera were
collected and stored at −70 °C. Inguinal LN biopsies and rectal
pinch biopsies (10 pinches per animal) were obtained from
immunized and control macaques 30 days before and on days
13 and 64 following CD8 depletion. The LNs were minced, and
the released lymphocytes were washed 2 times in PBS
containing 2% FCS and left overnight at 37 °C in standard
R10 medium before use in intracellular cytokine staining (ICS)
assays for IFN-γ. The rectal biopsies were minced in a Petri
dish, then 15 ml of prewarmed R10 containing Collagenase II
(50 U/ml, Sigma cat. #C-6885) was added and the tissues were
placed in a belly dancer water bath for 15 min at 37 °C. The
cells were washed by adding 15 ml of R10 or PBS and spinning
at 1200 rpm for 10 min. The supernatant was removed, and the
pellet was resuspended in 15 ml R10 plus Collagenase II (50 U/
ml), and incubated 15 min, at 37 °C. The cells were washed,
and the procedure was repeated 3 times. After the final
washing, the cells were left overnight at 37 °C in R10. The next
day, the cells were pushed through a 70-μm filter and counted
prior to use.
Anti-CD8 antibody administration
Nine months after the SIVmac251 re-challenge, the 8 durably
protected rhesus macaques and one SIV chronically infected,
unimmunized macaque (#39) were administered the mouse-
human chimeric monoclonal antibody to CD8 (cM-T807)
(Schmitz et al., 1999a, 1999b). Another SIV chronically
infected, unimmunized macaque (#34) was administered a
control isotype antibody, Synagis (MedImmune, Inc., Gaithers-
burg, MD), in order to demonstrate that any change in viremia
or CD8+ T cell counts was due to CD8 depletion rather than a
response to the IgG itself. Antibodies were given subcutane-
ously at day 0 at 10 mg/kg of body weight, and at days 3 and 7
intravenously at 5 mg/kg of body weight.
Viral RNA measurement
Viral RNA in plasma was quantitated by using the nucleic
acid sequence-based amplification technique (NASBA) as
described previously (Romano et al., 2000). In this ECL-
based detection assay RNA was quantitated with a standard
sensitivity threshold of <2000 copies/input volume plasma. An
assay with intermediate sensitivity (<500 copies/input volume
of plasma, generally 1 ml) was also used where necessary. A
real-time NASBA assay with a sensitivity of <50 copies/input
volume was used to evaluate plasma from macaques that were
consistently negative by the ECL-based assay. For the real-time
assay, macaque plasma was clarified by centrifugation at
2300×g for three minutes. The clarified plasma (0.5 ml to
1 ml) was then centrifuged at 49100×g for 60 min, and the viruspellet was then lysed in 1 ml lysis buffer. Nucleic acid was
isolated as described before (Romano et al., 2000), and the
extracted RNA was used in real-time NASBA. The final
NASBA reaction (20 μl) contained 5 μl of nucleic acid extract
and 40 mM Tris, pH 8.5, 12 mM MgCl2, 90 mM KCl, 5 mM
dithiothreitol, 1 mM each dATP, dCTP, dGTP, dTTP; 2.0 mM
each ATP, CTP, UTP; 1.5 mM GTP, 0.5 mM ITP, 0.1 μg/μl
BSA, 1.5 M Sorbitol, 0.08 U RNase H, 32 U T7 RNA
polymerase, 6.4 U avian myeloblastosis virus reverse transcrip-
tase (AMV-RT), 0.01 μM SIV wild type (WT) molecular
beacon probe, 0.1 μM SIV calibrator (Q) molecular beacon
probe, 0.2 μM each of the two amplification oligonucleotides,
and 15% DMSO. The SIV WT molecular beacon had the
fluorophore FAM linked to the 5′end and a quencher linked to
the 3′end, whereas the SIV Q molecular beacon had the
fluorophore 6-ROX linked to the 5′end and a quencher linked to
the 3′ end. For the assay all the components, except enzymes
and BSA, were mixed and preincubated at 65 °C for 2 min. The
reaction mixture was then cooled for 2 min at 41 °C and the
BSA and enzymes added. The reaction mixture was then placed
in the NucliSens EasyQ Analyzer (BioMerieux) and subjected
to isothermal amplification at 41 °C for 90 min. An algorithm
was then applied to calculate the SIV RNA copy number in the
plasma sample. The assay had a lower limit sensitivity of 50
copies of RNA, and the SIV RNA load was expressed as viral
RNA copies per 0.5 or 1 ml plasma.
For viral load quantification in tissues, total RNA was
extracted from homogenized tissues by a method described
previously (Chomczynski and Sacchi, 1987). Briefly, a small
portion of the tissue was excised and lysed by homogenizing in
a tube homogenizer with sodium citrate lysis buffer (pH 7.0)
containing guanidine thiocyanate, sarcosyl, and β-mercap-
toethanol. The lysed sample was treated with sodium acetate,
extracted with phenol:chloroform (5:1) and RNA was precip-
itated with isopropanol. Extracted RNAwas further purified by
dissolving the pellet in sodium citrate lysis buffer and by
reprecipitating with isopropanol. After washing with 70%
ethanol, the RNA pellet was air dried, dissolved in water, and
RNA content was quantitated by measuring 260-nm optical
density. Quantitation of viral RNA was performed on a small
aliquot (0.5 to 1 μg) of total RNA extract by NASBA. The assay
had a lower limit sensitivity of 500 copies of RNA, and the SIV
RNA load was expressed as viral RNA copies per microgram of
total tissue RNA.
ELISPOT
The number of freshly isolated PBMC secreting IFN-γ in
response to SIV Gag, Env, Nef, and Rev peptide pools was
measured by a standard ELISPOT assay as described in detail
elsewhere (Patterson et al., 2003). Env, Nef, and Rev peptides
were 15-mers overlapping by 11 amino acids. The Gag peptides
were 20-mers overlapping by 10 amino acids. Background counts
in wells containing medium only have been subtracted from all
reported values. A positive ELISPOT response was defined as
equal to or greater than the number of background spot forming
cells (SFC) plus 2 standard deviations. SFC resulting from
96 N.V. Malkevitch et al. / Virology 353 (2006) 83–98stimulation with 3 Env and 2 Gag peptide pools spanning the
entire proteins were summed and reported as single values.
Proliferation assay
T cell proliferative responses of viably frozen PBMC to
native endotoxin-free SIV gp120, SIV p27 (Advanced
BioScience Laboratories, Inc.), and Aldrithiol-2-inactivated
SIVmac239 (Ald-SIV; AIDS Vaccine Program, SAIC, NCI-
Frederick, Frederick, MD) were measured by incorporation of
3H thymidine (1 μCi/well) as described previously (Malkevitch
et al., 2003).
Intracellular IFN-γ staining
After overnight incubation, fresh cells (1 × 106) from LN or
rectal pinches were incubated at 37 °C for 1 h with a mixture of
Env, Gag, or Nef peptide pools (1 μg/ml per peptide) or with no
peptides as a negative control and then were treated with 10 μg/
ml of Brefeldin A (Sigma) for the next 4–5 h at 37 °C in order to
inhibit export of protein from the endoplasmic reticulum. The
cells were washed two times with FACS buffer (PBS and 2%
FCS) and stained for 20 min in the dark with 20 μl anti-CD3-
FITC (BD Pharmingen), 10 μl anti-CD8-RPE (DAKO) and
20 μl anti-CD4-PerCP (BD Pharmingen), then washed twice
with FACS buffer and fixed with 100 μl buffer A (Caltag) for
15 min at room temperature and washed again. The cells were
permeabilized with 100 μl buffer B (Caltag) and stained with
5 μl of anti-IFN-γ APC (BD Pharmingen) for 15 min in the
dark, at room temperature. The cells were washed once with
FACS buffer and re-fixed with 450 μl 2% PFA. Flowcytometry
acquisition was performed within the next 48 h. For LN cells, a
minimum of 10,000–100,000 events were acquired, and for
rectal cells, 3000–10,000 events.
Antibody assays
Serum binding antibodies to SIVmac251 gp120, p27, and Nef
were determined by enzyme-linked immunosorbent assay
(Buge et al., 1997). Binding titers were defined as the reciprocal
of the serum dilution at which the absorbance of the test serum
was twice that of the negative control serum diluted 1:50. IgG
and IgA SIVmac251 gp120-specific binding antibodies in saliva
and rectal secretions were assessed as previously described
(Malkevitch et al., 2004). Neutralizing antibodies against
laboratory-adapted SIVmac251 were evaluated in macaque sera
as described previously (Zhao et al., 2003b). Fifty percent
endpoint titers are reported.
Serum antibodies mediating ADCC were assessed using a
flow-cytometric method as described previously (Gómez-
Román et al., 2006). Human PBMC were used as effector
cells. Killing of two types of target cells consisting of H9 cells
infected with SIVmac251 and CEM.NKr cells coated with
SIVmac251 gp120 was evaluated. Antibody titers are expressed
as the reciprocal of the serum dilution at which percent killing
was equal to or greater than percent killing of negative control
samples plus three standard deviations.Statistical analysis
The statistical method used to analyze ELISPOT responses
was the fitting of a Bernoulli/lognormal mixture model with left
censoring for the responses to the four peptides at each week
(Moulton and Halsey, 1995). The Bernoulli component was
assumed to have a logistic regression form. A threshold of 10
was set for each raw count adjusted for its background level
(media mean plus 2 standard deviations). Fixed effects for the
individual peptides and the groups and random effects for the
correlation within macaques were included in the models.
Differences between groups of macaques were assessed using
the likelihood ratio test, except when all the adjusted counts
were zero for one group, in which case the exact permutation
distribution was used. The proliferative responses were
analyzed by repeated measures analysis of variance, adjusting
for the correlations over time in the responses to each antigen,
after a power transformation for variance stabilization. The P
values have been corrected for the multiple tests of the four
antigens compared simultaneously between groups.
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